[º¸°ÇŸÀÓÁî] ±¹¸³¾Ï¼¾ÅÍ(¿øÀå ¼È«°ü)´Â ÃÖ±Ù ¼¿ï·Ôµ¥È£ÅÚ¿¡¼ °³ÃÖµÈ ‘Á¦2ȸ ¾Æ½Ã¾ÆÁ¾¾çÇÐȸ ±¹Á¦Çмú´ëȸ(AOS 2022)¿Í Á¦48Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ’¿¡¼ ±¹¸³¾Ï¼¾ÅÍ ÀÇ·áÁø°ú ¿¬±¸ÁøÀÌ ÃÑ 6°³ÀÇ Çмú»óÀ» µ¿½Ã ¼ö»óÇß´Ù°í ¹àÇû´Ù.
°ø¼±¿µ Áø´Ü°Ë»çÀÇÇаú Àü¹®ÀÇ´Â ‘Cancer Research and Treatment’ÀÇ ³í¹® ½É»çÀ§¿øÀ¸·Î È°µ¿ÇÏ¸ç °´°üÀûÀÌ°í Ÿ´çÇÑ ½É»çÀÇ°ßÀ¸·Î ³í¹®ÀÇ ÁúÀû Çâ»ó°ú ¾ÏÇÐȸÁö ¹ßÀü¿¡ ±â¿©ÇÑ °ø·Î¸¦ ÀÎÁ¤¹Þ¾Æ Á¦14ȸ ´ëÇѾÏÇÐȸÁö Best Reviewer»óÀ» ¼ö»óÇß´Ù.
ÀÌ¿µÁÖ Æó¾Ï¼¾ÅÍ Ç÷¾×Á¾¾ç³»°ú Àü¹®ÀÇ´Â ‘Sequential Treatment with an Immune Checkpoint Inhibitor Followed by a Small-Molecule Targeted Agent Increases Drug-Induced Pneumonitis’·Î ‘Á¦12ȸ ´ëÇѾÏÇÐȸ ¸ÓÅ© ¾ÏÇмú»ó’À», ‘Patient-derived cells (PDCs) recapitulate tumor heterogeneity (TH) to target therapy in advanced lung cancer patients’·Î AOS 2022ÀÇ Best Oral Presentation Award¸¦ ¼ö»óÇØ 2°³ÀÇ »óÀ» ¼ö»óÇÏ´Â ¿µ¿¹¸¦ ¾È¾Ò´Ù.
¼¹Î¾Æ ¾Ï°ËÁø»ç¾÷ºÎÀåÀº ‘Trends in Cancer Screening Rates among Korean Men and Women: Results of the Korean National Cancer Screening Survey, 2004-2018’ ³í¹®À¸·Î ´ëÇѾÏÇÐȸ ¿ì¼ö³í¹®»óÀ» ¼ö»óÇß´Ù.
¶Ç, À¯¿¹ºó Ç¥ÀûÄ¡·á¿¬±¸°ú ¿¬±¸¿øÀº ‘Established patient-derived organoids using ascites fluid or pleural effusion in cancer patients’·Î AOS 2022ÀÇ Best Oral Presentation Award¸¦, À¯³²Èñ »ý¹°Á¤º¸¿¬±¸°ú ¿¬±¸¿øÀº ‘Identification of resistance mechanisms and new treatments for advanced lung cancer based on patient-derived cell’·Î Best Poster Presentation Award¸¦ °¢°¢ ¼ö»óÇß´Ù.